Loading...
XASX
IPD
Market cap7mUSD
Oct 09, Last price  
0.01AUD
1D
20.00%
1Q
20.00%
Jan 2017
-99.41%
IPO
-99.29%
Name

ImpediMed Ltd

Chart & performance

D1W1MN
XASX:IPD chart
P/E
—
P/S
0.86
EPS
—
Div yield, %
—
Shrs. gr., 5y
12.16%
Rev. gr., 5y
11.69%
Revenues
15m
+14.85%
02,311,3992,991,9533,639,0003,887,0002,945,0002,733,0003,521,0004,844,0005,791,0005,766,0003,318,0004,156,0005,741,0008,409,00010,566,00011,344,00010,319,00012,724,00014,613,000
Net income
-25m
L+7.19%
0-9,754,128-14,027,655-11,402,000-14,822,000-12,342,000-8,464,000-7,935,000-14,797,000-25,980,000-27,571,000-27,248,000-23,996,000-21,377,000-20,706,000-19,874,000-20,521,000-19,790,000-23,237,000-24,907,000
CFO
-20m
L+36.78%
0-7,416,381-11,786,199-10,386,000-11,299,000-11,797,000-7,675,000-6,802,000-10,757,000-22,422,000-25,566,000-23,458,000-19,588,000-19,218,000-13,258,000-15,664,000-18,049,000-17,789,000-14,645,000-20,031,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ImpediMed Limited is a medical technology firm that specializes in software solutions. The company is involved in the creation, production, and global distribution of sophisticated bioimpedance spectroscopy (BIS) equipment and its accompanying software applications, serving markets in Australia, North America, and beyond. Its principal offerings include: SOZO: A non-intrusive BIS device engineered for the evaluation of lymphedema and for tracking fluid levels in individuals afflicted with heart failure. SFB7: A single-channel, tetrapolar BIS instrument utilized to assess the body composition of healthy individuals. ImpediVET: Another single-channel, tetrapolar BIS device, tailored specifically for veterinary applications to measure fluid status and tissue characteristics in animals. ImpediMed primarily markets its advanced medical devices to healthcare institutions such as hospitals and clinics. The company was founded in 1999 and its headquarters are located in Pinkenba, Australia.

Key people

Christine Emmanuel-Donnelly
Non-Executive Independent Chairman of the Board · since 2024
Scott Long
Senior Vice President - Sales, Key Accounts and Renewals · since 2025
Mike Bassett
Vice President - Business Development and Investor Relations · since 2025
Parmjot Bains
Interim Chief Executive Officer, Managing Director, Executive Director · since 2024
Julie Kuhlken
Senior Director - Marketing · since 2024
Mcgregor Grant
Chief Financial & Operating Officer, Executive Director · since 2024
Ashley Munoz
Director - Human Resources · since 2024
Steven Chen
Chief Medical Officer · since 2023
Katie Newsome
Clinical Program Director · since 2024
Scott Savage
Chief Product Officer · since 2025
Leanne Ralph
Company Secretary · since 2015
Andrew Grant
Director · since 2024
Fiona Bones
Non-Executive Independent Director · since 2024
Janelle Delaney
Non-Executive Independent Director · since 2023
URL
https://www.impedimed.com
IPO date
Oct 24, 2007
Employees
76
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT